Lung Cancer

New Initiative Aims to Foster Informed Discussions Between Newly Diagnosed Lung Cancer Patients, Caregivers and Their Healthcare Team
 

Lung cancer survivors stage a takeover of Lung Cancer Foundation of America’s social media channels on World Lung Cancer Day August 1 to demonstrate what it means to be #livingwithlungcancer.
 

An expert sheds light on the importance of genomics in treating lung cancer.

In an interview with CURE®, Dr. Jorge Gomez discussed how recent developments in the assessment of biomarkers within the small cell lung cancer and non-small cell lung cancer space have led to approvals of new and expanded therapies.
 

Dr. Timothy Burns, of UPMC Hillman Cancer Center, discusses developments in the treatment of lung cancer over the next several years that have exciting potential to impact the field.
 

The Food and Drug Administration in May approved 7 therapies to treat patients with non-small cell lung cancer. And although one expert notes that few are considered “practice changing”, patients should not be disheartened considering there have been so many advancements in the treatment of the disease.
 

Most of the data from the recent approvals of several non-small cell lung cancer drugs don’t distinguish themselves regarding efficacy or safety to what was already available before the flurry of approvals in May, according to Dr. Timothy Burns.
 

“One FDA approval that we were quite excited about (is Tabrecta). And I've actually already put some patients on it; it's a very good drug,” Dr. Timothy Burns said in a recent interview.
 

The recent surge of drug approvals in the non-small cell lung cancer (NSCLC) space by the Food and Drug Administration (FDA) is quite unusual and only a fraction of them are considered practice changing, according to Dr. Timothy Burns.
 

An expert explains the importance of the fourth approval of the immunotherapy Tecentriq for certain patients with metastatic non-small cell lung cancer who have a high PD-L1 expression.